Navigation Links
Misonix Reports Strong Revenue Increases for the First Quarter of Fiscal 2013

FARMINGDALE, N.Y., Nov. 7, 2012 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for spine surgery, cranial maxillo – facial surgery, neurosurgery,  wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, today reported financial results for the first quarter of fiscal year 2013, ended September 30, 2012.

Highlights for the quarter and the fiscal year include:

  • Revenue for the first quarter of fiscal 2013 increased 42% to $4.6 million compared to $3.2 million in the comparable quarter of fiscal 2012.
  • U.S. revenue increased 30%, International revenue increased 58% versus the first quarter of fiscal 2012.
  • Gross margin increased 490 basis points to 59.7% for the three months ended September 30, 2012 versus 54.8% in the first quarter of 2012.
  • BoneScalpel™ revenue increased 220% for the first quarter of 2013 versus the prior year three month period.
  • SonicOne™ revenue increased 97% for the first quarter versus the comparable quarter of fiscal 2012.
  • SonaStar™ revenue increased 21% for the first quarter versus the last year's comparable quarter.
  • Net income for the quarter was $44,834, or $0.01 per diluted share, compared to a net loss of $883,942, or $(0.13) per diluted share in the first quarter of 2012.
  • Cash and cash equivalents totaled $6.7 million at September 30, 2012 with no long-term debt.
  • Q1 2013 Financial Results:
    For the first quarter of fiscal 2013, revenue increased 42% to $4.6 million compared to $3.2 million in the first quarter of 2012. BoneScalpel revenue for the quarter increased 220% to $2.1 million compared to $655,686 in last year's first quarter. SonicOne revenue increased 97% to $500,886 compared to $254,387 in the first quarter last year. SonaStar revenue increased 21% to $1.6 million compared to $1.3 million in the first quarter last year.

    Gross margin increased to 59.7% for the first quarter of fiscal 2013 from 54.8% for the first quarter ended September 30, 2012. Operating expenses for the first fiscal quarter increased nine percent primarily attributable to continued expansion of the Company's in-house sales force, commissions on expanded product sales and increased advertising and depreciation expense due to increased rented/leased/no-cap units in the field. Income from continuing operations before income taxes for the quarter was $40,016 compared to a loss from continuing operations before income taxes of $799,026 in the first quarter of 2012.

    The financial results for the first quarter included net income from discontinued operations of $6,318, or $0.00 per fully diluted share – adjusted for taxes – primarily related to the sale of the Company's Laboratory and Forensic Safety Products business.

    For the first quarter of fiscal year 2013, the Company reported net income of $44,834, or $0.01 per diluted share, compared to a net loss of $833,942, or $(0.13) per diluted share, in the first quarter of fiscal 2012.

    Michael A. McManus Jr., President and Chief Executive Officer of Misonix, commented, "We are off to a very good start in fiscal 2013. We achieved strong revenue growth across our major product lines. First quarter sales in the U.S. increased 30% and International sales increased 58% as our distribution networks continue to gain traction. We had exceptionally strong revenue increases in Asia, Australia, South America and South Africa.

    "We continue to expand our distribution capabilities both in and outside the U.S. We are beginning to see the acceptance of our SonicOne for the treatment of wounds in operating room procedures. We are pleased with the way that our products are being accepted by the surgical community worldwide. Our BoneScalpel enables surgeons to make precision cuts in bone – from the spine to the skull and on to delicate facial surgical procedures – while avoiding damage to soft tissue and nerves in a manner that will result in better patient outcomes, improved quality of life, and generate cost efficiencies across the patient's treatment continuum."

    "I was very excited by the reception that our BoneScalpel product received at the recent North American Spine Society Show (NASS) in Dallas," commented Mr. McManus. "We met with a number of surgeons that have recently integrated the BoneScalpel into their respective practices and we are very pleased with the positive comments made relating to ease of use of the instrument, the reduction of time in completing procedures and patient outcomes.

    "During the NASS event, Isador H. Lieberman, MD, MBA, FRCSC, of the Scoliosis and Spine Tumor Center, Texas Back Institute, Plano, Texas, released an abstract of a paper submitted for publication based on the results of 128 patients that he treated utilizing the BoneScalpel.  Dr. Lieberman concluded that "the BoneScalpel is a safe and effective ultrasonic bone cutting device that can be used to facilitate osteotomies in a variety of spine surgeries. This device eliminates the risk of soft tissue injury associated with the use of high speed burrs and oscillating saws during spine surgery.

    "In addition, at NASS, there were presentations highlighting outcomes when the BoneScalpel was used as the exclusive bone cutting tool in complex, spine deformity cases, plus a special Bio-Skills Laboratory was conducted where 46 spine surgeons were exposed to the clinical benefits of the BoneScalpel. All things considered, the NASS was an extraordinary event."

    Mr. McManus concluded, "We continue to have a solid balance sheet with $6.7 million in cash and equivalents and zero long-term debt. We are pleased with the progress and the measurable results that indicate success in the execution of our strategic plan as a focused medical device company."

    Conference Call:
    Michael A. McManus Jr., President and Chief Executive Officer, and Richard Zaremba, Senior Vice President and Chief Financial Officer, will host a conference call Wednesday, November 7, 2012 at 4:30 pm ET to discuss the Company's first quarter results.

    Shareholders and other interested parties can access the conference call by dialing (877) 317-6789 or (412) 317-6789 or can listen via a live Internet webcast, which is available in the Investor Relations section of the Company's website at

    A teleconference replay of the call will be available for three days at (877) 344-7529 or (412) 317-0088, confirmation # 10020438. A webcast replay will be available in the Investor Relations section of the Company's website at for 30 days.

    About Misonix:
    Misonix, Inc. designs, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at

    With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Investors are cautioned that forward looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships,  regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10 K, subsequent Quarterly Reports on Form 10 Q and Current Reports on Form 8 K.  The Company disclaims any obligation to update its forward looking relationships.Misonix Contact: 

    Investor Relations Contact:Richard ZarembaJoe Diaz, Lytham Partners631 694 9555

    602 889 

    mson@lythampartners.comMISONIX, INC. And SubsidiariesConsolidated Statements of OperationsUnauditedThree Months EndedSeptember 30,2012

    2011Net sales


    $3,217,199Cost of goods sold


    1,453,407Gross profit


    1,763,792Selling expenses


    1,180,252General and administrative expenses


    1,167,820Research and development expenses


    309,974Total operating expenses


    2,658,046Loss from operations


    (894,254)Total other income


    95,228Income (loss) from continuing operations before
    income taxes


    (799,026)Income tax expense


    4,960Net income (loss) from continuing operations


    (803,986)Discontinued operations:Net income (loss) from discontinued operations, net
      of tax of $0 and $0, respectively 


    (79,956)Net income (loss) from discontinued operations


    (79,956)Net income (loss) 


    ($883,942)Net income (loss) per share from continuing


    ($0.12)Net income (loss) per share from discontinued


    (0.01)Net income (loss) per share-Basic


    ($0.13)Net income (loss) per share from continuing


    ($0.12)Net income (loss) per share from discontinued


    (0.01)Net income (loss) per share-Diluted


    ($0.13)Weighted average common shares-basic


    7,001,370Weighted average common shares-diluted


    7,001,370MISONIX, INC. And Subsidiaries Consolidated Balance SheetsSeptember 30, 2012June 30,
    2012(Unaudited)(derived from auditedfinancial statements)AssetsCurrent Assets:  Cash and cash equivalents$
    ,273,015  Accounts receivable, less allowancefor doubtful accounts of $169,641
    and $155,739, respectively2,612,1713,158,084  Inventories, net4,211,3824,380,841  Prepaid expenses and other current assets223,928306,691  Note receivable74,867198,117Total current assets13,785,01514,316,748Property, plant and equipment, net809,231891,822Goodwill1,701,0941,701,094Intangible and other assets1,342,5841,403,173Total assets$17,637,924$18,312,837Liabilities and stockholders' equityCurrent liabilities:  Accounts payable$
    ,507,695  Accrued expenses and other current liabilities849,1011,074,932Total current liabilities1,774,7852,582,627Deferred income106,094117,147Deferred lease liability23,19922,996Total liabilities1,904,0782,722,770Commitments and contingenciesStockholders' equity:  Capital stock, $0.01 par value - shares authorized
    20,000,000, 7,082,920 shares issued and
    7,005,360 shares outstanding70,82970,829  Additional paid-in capital26,231,89626,132,951  Accumulated deficit(10,157,886)(10,202,720)  Treasury stock, at cost, 77,560 shares(410,993)(410,993)Total stockholders' equity15,733,84615,590,067Total liabilities and stockholders' equity$17,637,924$18,312,837

    SOURCE Misonix, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Misonix Announces New Distribution Agreement For Panama
    2. Misonix And SIAD Healthcare Renew Distribution Agreement For Italy
    3. Misonix Exhibits at Major Worldwide Spine Conference
    4. Misonix Adds Industry Veteran To Management Team
    5. Misonix Participates In Cleveland Spine Review
    6. Misonix And Soelim Create New Distribution Alliance For South Korea
    7. Misonix Inks New Distribution Agreement For Croatia And Slovenia
    8. Misonix Attends International Meeting On Advanced Spine Techniques (IMAST) - Introduces New Product
    9. Misonix Adds 6 Spine Sales Agencies In The U.S.
    10. Misonix Product Featured At Neurosurgery Congress
    11. Misonix Reports Strong Revenue Increases for the Three Months and Full-Year Ended June 30, 2012
    Post Your Comments:
    (Date:3/27/2017)... 2017  Impax Laboratories, Inc. (NASDAQ: IPXL)today announced that ... Bisaro as Impax,s President and Chief Executive Officer ... 27, 2017. Mr. Bisaro will succeed J. Kevin ... Chief Executive Officer since December of 2016. ... experience, Mr. Bisaro, 56, is an accomplished global business ...
    (Date:3/27/2017)... , March 27, 2017 Invivotek, LLC, a ... in vivo pharmacology contract research organization (CRO), ... to its newly expanded preclinical research facility in ... provides a cleaner, renewable energy source to reduce costs ... Completion of the Genesis Solar Farm follows Invivotek,s recent ...
    (Date:3/24/2017)... 24, 2017  Zymo Research Corp., also ... Robotics, Inc., who designs, manufactures and distributes ... that teams Zymo Research,s DNA methylation detection ... extraction products with Hamilton,s high-throughput automation platforms. ... for microbiomics and RNA isolation for use ...
    Breaking Medicine Technology:
    (Date:3/27/2017)... Clearwater, FL (PRWEB) , ... March 27, 2017 ... ... accepts new patients for clear braces. People who want straight teeth without the ... Invisalign® in Clearwater, FL, without acquiring a referral. A custom-designed series ...
    (Date:3/27/2017)... VA (PRWEB) , ... March 27, 2017 , ... ... 3.0 was transitioned to the OSEHRA popHealth Community in 2014. It ... Work Group and the Developer Open Source Project Group. OSEHRA Organizational Member Zato ...
    (Date:3/27/2017)... ... March 27, 2017 , ... ... CE Certificate of Conformity for the Smart System® 20/20. CE Certification builds upon ... industry standards and specifications such as ANSI, ISO and proven test methods used ...
    (Date:3/27/2017)... ... 27, 2017 , ... Advantexe Learning Solutions , a ... a new research study, The Business Readiness Report. The report explores the correlation ... the actual success of achieving individual and company goals. , There are ...
    (Date:3/27/2017)... ... March 27, 2017 , ... According to the ... including all stages, is more than 95%. Once the cancer spreads to other organs, ... 30%. To find out how to avoid this latter group, tune in to ...
    Breaking Medicine News(10 mins):